Amedisys Inc

Amedisys — Q2 2020 Earnings Presentation

23 slides from Amedisys's earnings presentation, Jul 28, 2020

  1. Slide 1: Amedisys Second Quarter 2020 Earnings Call Supplemental Slides

    Amedisys Second Quarter 2020 Earnings Call Supplemental Slides July 29th, 2020 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cau

  3. Slide 3: Q2 2020 Results

    Q2 2020 Results amedisys

  4. Slide 4: Our Key Areas of Focus

    Our Key Areas of Focus Strategic areas of focus and progress made during Q2’20 Home Health*: Total same store admissions -9%, Total same store volume -2% June Results: Same Store Admissions: +5%, Same Store Volume: +8% Hospice: Admissions -1%, ADC: flat June Results: Same Store Admissions: +8% Perso

  5. Slide 5: Highlights and Summary Financial Results (Adjusted): 2Q 2020

    Highlights and Summary Financial Results (Adjusted): 2Q 2020(1) Home Health total same store volume -2%, total same store admissions -9%; Hospice same store ADC flat Amedisys Consolidated Revenue Growth: -3% EBITDA: $66M (+8%) EBITDA Margin: 14% (+140 bps) EPS: $1.34 (+11%) 2Q’20 Net debt: $299.2M N

  6. Slide 6: Our revenue sources: 2Q'20

    Our revenue sources: 2Q’20 Medicare FFS: Reimbursed over a 30-day period of care Private Episodic: MA and Commercial plans who reimburse us over a 30-day period of care. Generally at rates ~90% – 100% of Medicare Per Visit: Managed care, Medicaid and private payors reimbursing us per visit performed

  7. Slide 7: Home Health and Hospice Segment (Adjusted) – 2Q 2020

    Home Health and Hospice Segment (Adjusted) – 2Q 2020(1) Revenue per Episode down 2.3% Sequestration suspension benefit $3M Y/Y CPV up +$2.82 (+3.1%, raises effective 8/1) Visits per Episode decreased 1.9 Home Health Highlights Same store average daily census (ADC) flat Net revenue per day +1.9% Sequ

  8. Slide 8: General & Administrative Expenses – Adjusted

    General & Administrative Expenses – Adjusted (1,2) Notes: Year over year total G&A as a percentage of revenue increased 160 basis points ($4 million) Year over year G&A increase as a percent of revenue due to the impact of COVID-19 on volumes/revenues (~$52M impact for the quarter net of sequestrati

  9. Slide 9: Home Health cost per visit components

    Components 2Q19 1Q’20 2Q’20 YoY Variance Detail Initiatives Salaries $61.69 $64.42 $63.03 $1.34 YoY increase due to planned wage increases partially offset by optimization of discipline mix. Also, YoY increase due to fixed costs (training, PTO, etc.) on lower visits Staffing mix optimization, produc

  10. Slide 10: Driving Top Line Growth

    Driving Top Line Growth Growth in all three lines of business impacted by COVID-19 but recovering. Exited the quarter with growth in Home Health and Hospice segments Home Health Total Volume Hospice ADC Personal Care Total Hours / Quarter

  11. Slide 11: Industry Leading Quality Scores

    Industry Leading Quality Scores Note: Top Competitor Avg weighted by CCN count and includes LHC, Kindred, AFAM, EHC and BKD Metric OCT 19 Release JAN 20 Release APR 20 Release Oct 20 PREVIEW Quality of Patient Care 4.28 4.27 4.26 4.41 Entities at 4+ Stars 88% 86% 86% 92% Metric JUL 19 Release OCT 19

  12. Slide 12: Hospice Quality: Moving Towards Best-in-Class Hospice Quality

    Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class Hospice Quality

  13. Slide 13: Debt and Liquidity Metrics

    Debt and Liquidity Metrics ~Net leverage ~1.3x Net debt defined as total debt outstanding ($406.5M) less cash ($107.3M). Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($228.8M). Liquidity defined as the sum of cash balance and available revolving line of c

  14. Slide 14: Cash Flow Statement Highlights

    Cash Flow Statement Highlights (1) Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments.

  15. Slide 15: Income Statement Adjustments

    Income Statement Adjustments (1) The financial results for the three-month periods ended June 30, 2019, September 30, 2019, December 31, 2019, March 31, 2020 and June 30, 2020 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP fin

  16. Slide 16: 2020 Guidance Update

    2020 Guidance Update 6 amedisys

  17. Slide 17: Amedisys 2020 Reinstated Guidance

    Amedisys 2020 Reinstated Guidance 2020 Original Guidance 2020 Reinstated Guidance Revenue $2,115M - $2,160M $2,040M - $2,070M Adjusted EBITDA $250M - $260M $245M - $255M Adjusted Earnings per Share $4.90 - $5.13 $4.84 - $5.06 Note: Adjusted numbers are ex-Care’s Act funds Reinstated guidance does no

  18. Slide 18: Reimbursement Outlook

    Reimbursement Outlook Reimbursement Impact for Home Health and Hospice Home Health Hospice 2020 Final Rule (PDGM – Behavioral Assumptions) (4.36%) Estimated AMED-Specific Impact (2.8%) 2020* Market Basket Update 3.0% Productivity / Other Adjustment (0.4) Estimated Industry Impact +2.6% Estimated AME

  19. Slide 19: Our Path Forward: 2021 & Beyond

    Our Path Forward: 2021 & Beyond 2021 & Beyond – The Future Is Very Bright for AMED Entering 2021 with all PDGM cost levers in place Continued strategic acquisitions of Home Health and Hospice assets – Home Health market share absorption strategy delayed until early 2021 due to Cares Act funds FY 202

  20. Slide 20: COVID-19

    COVID-19 6 amedisys

  21. Slide 21: COVID-19 Impact Q2'20: admits and referrals recovering

    *Baseline defined as referrals and admits from pre-Covid-19 timeframe of 1/5/20 – 3/14/20 HH: Consolidated Same Store HOSP: AMED + CCH (ex. Asana & Aseracare) *Baseline defined as referrals and admits from pre-Covid-19 timeframe of 1/5/20 – 3/14/20 Consolidated Same Store Consolidated Same Store (CC

  22. Slide 22: COVID-19 Impact on Q2'20 Home Health volume and PPE inventory

    *Baseline defined as total admits + recerts from pre-Covid-19 timeframe of 1/5/20 – 3/14/20 HH: Consolidated Same Store COVID-19 Impact on Q2’20 Home Health volume ~98% of pre-COVID levels, missed visits related to COVID-19 significantly down and robust PPE inventory on hand PPE Item Units (M) Cost

  23. Slide 23: Care Center Count by State

    State Home Health Hospice Total Georgia 60 10 70 Tennessee 45 15 60 Alabama 30 13 43 Pennsylvania 7 25 32 South Carolina 21 8 29 Florida 18 5 23 Virginia 13 6 19 Kentucky 17 - 17 West Virginia 11 6 17 Louisiana 10 5 15 Massachusetts 5 10 15 Maryland 9 3 12 Texas 1 12 13 Indiana 5 6 11 Mississippi 9

Amedisys — Q2 2020 Earnings Presentation on 6ix